Malaria Information and Prophylaxis, by Country [G]

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Gabon All Chloroquine P. falciparum 90%,

P. malariae, P. ovale, P. vivax 10% combined

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Gambia, The All Chloroquine P. falciparum ≥ 85%,

P. ovale 5%-10%,

P. malariae, P. vivax rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Georgia None Not Applicable Not Applicable Not Applicable
Germany None Not Applicable Not Applicable Not Applicable
Ghana All Chloroquine P. falciparum 90%,

P. ovale 5-10%,

P. vivax rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine 6
Gibraltar (U.K.) None Not Applicable Not Applicable Not Applicable
Greece Rare local transmission May-November associated with imported malaria cases, in agricultural areas. None in tourist areas. Not Applicable P. vivax 100% None
Greenland (Denmark) None Not Applicable Not Applicable Not Applicable
Grenada None Not Applicable Not Applicable Not Applicable
Guadeloupe, including St. Barthélemy and Saint Martin (France) None Not Applicable Not Applicable Not Applicable
Guam (U.S.) None Not Applicable Not Applicable Not Applicable
Guatemala Rural areas only at altitudes < 1,500 m (4,921 ft). None in Antigua, Guatemala City, or Lake Atitlan. None P. vivax 97%,

P. falciparum 3%

Escuintla Province: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6

All other areas with malaria: Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine,6 or tafenoquine6.

Guinea All Chloroquine P. falciparum >85%,

P. ovale 5-10%,

P. vivax rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Guinea-Bissau All Chloroquine P. falciparum >85%,

P. ovale 5-10%,

P. vivax rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Guyana All areas. Rare cases in the cities of Amsterdam and Georgetown. Chloroquine P. falciparum 50%,

P. vivax 50%

Areas with malaria except the cities of Amsterdam and Georgetown: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Cities of Amsterdam and Georgetown: Mosquito avoidance only.

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2. Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
6. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine.

Page last reviewed: March 27, 2019